The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns and costs following metastatic breast cancer diagnosis in U.S. women: A SEER-Medicare analysis.
D. C. A. Taylor
Consultant or Advisory Role - Quality Metric
M. Sanon
Consultant or Advisory Role - Quality Metric
K. Clements
Consultant or Advisory Role - Quality Metric
S. Balu
Employment or Leadership Position - Eisai
Research Funding - Eisai
C. Faria
Employment or Leadership Position - Eisai
Research Funding - Eisai
A. Teitelbaum
Consultant or Advisory Role - Quality Metric